Skip to main content

Table 2 Relation between some clinical or tumor characteristics and tumor PET-derived image parameters in 143 patients with ER+/HER2- breast cancer

From: 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

Ā 

Age

Tumora

Lymph nodesa

Histology

Grade

PR expression

ā‰¤40

>40

ā‰¤50

>50

T2

T3

N0

N+

IDC

ILC

1ā€“2

3

Neg

Pos

No. patients

27

116

74

69

53

56

58

85

129

7

98

42

55

88

SUVmax

med

5.4

6.8

6.5

6.6

5.2

5.9

6.1

6.6

6.8

4.8

5.4

7.9

7.2

5.7

P

0.31

0.63

0.56

0.79

0.43

<0.01

0.06

SUVmean

med

3.1

3.6

3.4

3.6

2.9

3.3

3.5

3.5

3.6

3.0

3.1

4.2

4.0

3.2

P

0.36

0.67

0.59

0.77

0.31

<0.01

0.06

SUVpeak

med

4.3

5.3

5.1

5.1

4.1

4.9

4.9

5.1

5.2

4.4

4.4

6.4

5.7

4.5

P

0.32

0.60

0.44

0.81

0.63

<0.01

0.05b

MATV

med

10.1

11.2

11.0

9.6

6.7

10.8

9.2

11.3

10.1

32.5

10.9

10.4

13.9

9.1

P

0.33

0.86

<0.01

0.24

0.02b

0.83

0.03b

TLG

med

27.2

39.0

33.5

35.2

20.1

33.5

32.7

40.5

32.8

74.6

32.1

44.8

46.3

28.2

P

0.22

0.86

<0.01

0.41

0.16

0.05b

0.01b

H

med

0.12

0.12

0.12

0.12

0.11

0.12

0.12

0.12

0.12

0.14

0.12

0.12

0.13

0.12

P

0.81

0.87

0.02

0.10

0.09

0.73

0.12

E

med

3.5

3.8

3.7

3.6

3.2

3.7

3.5

3.8

3.6

4.8

3.7

3.7

4.0

3.5

P

0.18

0.97

<0.01

0.25

0.02b

0.70

0.02b

  1. P value for comparison of median values with the Wilcoxon rank sum test. Bold numerals correspond to P values keeping statistically significant after multiple corrections from Benjamini-Hochberg
  2. PET positron emission tomography, ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, PR progesterone receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, SUV standardized uptake value, MATV metabolically active tumor volume, TLG total lesion glycolysis, H homogeneity, E entropy
  3. aClinical classification according to the seventh edition of the AJCC Cancer Staging Manual
  4. bNot significant after correction for multiple testing